Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. Braftovi (encorafenib) capsules, Full Prescribing Information. 2. Food and Drug Administration. Immunogenicity testing of therapeutic protein products —developing and validating assays for anti-drug antibody detection Guidance for Industry. 2019. https://www.fda.gov/media/119788/download. Accessed 13 Nov 2023.
3. European Medicines Agency ICH Guideline M12. Drug Interaction Studies. 2022 https://www.ema.europa.eu/en/documents/scientific-guideline/draft-ich-guideline-m12-drug-interaction-studies-step-2b_en.pdf. Accessed 3 Aug 2023.
4. BRAFTOVI (encorafenib) capsules, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/210496s013lbl.pdf. Accessed 3 Aug 2023.
5. Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, et al. Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clin Cancer Res. 2017;23(18):5339–48.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献